Last updated: March 9, 2026
What is NDC 51407-0614?
NDC 51407-0614 refers to a specific drug product listed under the National Drug Code system. According to the FDA, this code corresponds to Zirabev (bevacizumab-bvzr), a biosimilar referencing Avastin (bevacizumab). Zirabev is used in oncology for metastatic cancers, including colorectal, lung, and kidney cancers.
Market Landscape
Regulatory Status
- Approval Date: FDA approved Zirabev in November 2019.
- Indications: Uses are FDA-approved for the same indications as Avastin, including metastatic colorectal carcinoma, non-squamous non-small cell lung cancer, and glioblastoma.
Competitive Environment
- Main Competitors:
- Avastin (originator branded drug)
- Other biosimilars (e.g., Mvasi, Zirabev is part of the ongoing biosimilar segment expansion)
- Market Share:
- Avastin holds approximately 85% of the bevacizumab market.
- Biosimilars, including Zirabev, account for 15%, with growth following increasing biosimilar acceptance.
- Pricing Trends:
- Biosimilar prices typically reduce healthcare costs by 15-30% relative to originators.
- Zirabev's list price in the U.S. is approximately 25-30% lower than Avastin (list prices roughly $5,000–$7,000 per vial depending on dosage).
Market Size Estimates
- The U.S. oncology biotech market for bevacizumab approximates $3.5 billion annually.
- Biosimilars command a growing segment, expected to expand at a CAGR of around 20% through 2027.
Pricing Analysis and Projections
Current Price Points
| Drug |
Approximate List Price (per vial) |
Indicated Use |
Market Share (Estimate) |
| Avastin |
$5,000–$7,000 |
Multiple solid tumors |
85% |
| Zirabev |
$3,750–$5,250 |
Similar indications, approved since 2019 |
10–15% |
Factors Influencing Price Trajectory
- Market Penetration: Increased adoption driven by cost savings.
- Reimbursement Policies: Shifts favoring biosimilars for cost containment.
- Regulatory Changes: Potential for expanded indications can increase volume.
- Patent and Exclusivity: Patent expiry for Avastin may influence biosimilar pricing dynamics in 2024–2026.
Future Price Projections (2023–2027)
| Year |
Estimated Price Range (per vial) |
Comments |
| 2023 |
$3,750–$5,250 |
Stabilized market share, existing price points |
| 2024 |
$3,600–$5,000 |
Patent expiries, increased biosimilar competition |
| 2025 |
$3,500–$4,900 |
Greater biosimilar market penetration |
| 2026 |
$3,400–$4,800 |
Possible biosimilar price wars, health system shifts |
| 2027 |
$3,300–$4,700 |
Mature biosimilar market, sustained cost savings |
Pricing Sensitivity
- Price reductions beyond 30% likely occur as biosimilar competition intensifies.
- Factors such as manufacturer rebates, hospital contracts, and payer negotiations can drive actual transaction prices below list prices.
Key Market Drivers
- Policies promoting biosimilar use.
- Competition from newer biosimilars.
- Volume growth from expanded indications.
- Economies of scale in manufacturing.
Risks and Opportunities
- Risks: Patent litigation delaying biosimilar uptake, payer resistance, and slower physician adoption.
- Opportunities: Cost-effective cancer treatment, increased market share due to price sensitivity, and potential for expanded indications.
Summary
Zirabev (NDC 51407-0614) operates in a highly price-sensitive oncology biosimilar market valued at roughly $3.5 billion annually in the U.S. Its pricing is expected to decline gradually over the next five years as biosimilar competition grows and patent protections for the originator expire. Current list prices for Zirabev range $3,750–$5,250 per vial, with projections indicating a slow downward trend aligned with increased adoption and regulatory shifts.
Key Takeaways
- Zirabev is a biosimilar to Avastin with stable market positioning since 2019.
- Price reductions are expected as biosimilar adoption accelerates, potentially reaching $3,300–$4,700 per vial by 2027.
- Market expansion depends on treatment guideline acceptance, payer policies, patent expirations, and competitive dynamics.
- Significant revenue potential exists through volume growth in existing and expanded indications.
- Cost pressures on healthcare providers will continue to support biosimilar uptake and price declines.
FAQs
-
When did Zirabev receive FDA approval?
Approved in November 2019.
-
What is Zirabev primarily used for?
Treats multiple solid tumors including colorectal, lung, and kidney cancers.
-
How does Zirabev’s price compare to Avastin?
It is typically priced 25–30% lower than Avastin.
-
What factors could influence further price declines?
Patent expiries, increased biosimilar competition, and payer negotiations.
-
What is the forecasted price trend for Zirabev by 2027?
Prices are expected to decline gradually, reaching approximately $3,300–$4,700 per vial.
References
[1] FDA. (2019). Approval Letter for Zirabev (bevacizumab-bvzr).
[2] IQVIA. (2022). Oncology Biosimilars Market Data.
[3] Evaluate Pharma. (2023). Oncology Biosimilars Market Forecast.
[4] U.S. Biosimilar Market Analysis. (2023). R&D Insights.
[5] CMS, Centers for Medicare & Medicaid Services. (2022). Reimbursement Policies for Biosimilars.
